Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial

BACKGROUND: Proprotein convertase subtilisin/kexin type 9 (PCSK9) binds to LDL receptors, leading to their degradation. Genetics studies have shown that loss-of-function mutations in PCSK9 result in reduced plasma LDL cholesterol and decreased risk of coronary heart disease. We aimed to investigate...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Lancet
Glavni autori: Fitzgerald, Kevin, Frank-Kamenetsky, Maria, Shulga-Morskaya, Svetlana, Liebow, Abigail, Bettencourt, Brian R, Sutherland, Jessica E, Hutabarat, Renta M, Clausen, Valerie A, Karsten, Verena, Cehelsky, Jeffrey, Nochur, Saraswathy V, Kotelianski, Victor, Horton, Jay, Mant, Timothy, Chiesa, Joseph, Ritter, James, Munisamy, Malathy, Vaishnaw, Akshay K, Gollob, Jared A, Simon, Amy
Format: Artigo
Jezik:Inglês
Izdano: 2013
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4387547/
https://ncbi.nlm.nih.gov/pubmed/24094767
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S0140-6736(13)61914-5
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items